Close Menu

Harold Varmus is stepping down from his post as president of Memorial Sloan-Kettering, reports ScienceInsider. In his email to Sloan-Kettering staff, Varmus says that he had only planned to run the institute for about 10 years — he joined Sloan-Kettering in 2000 — and that “the institution would now benefit from a fresh approach.” Varmus also says that he’ll stay on until his replacement is found and that replacement will have big shoes to fill.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.